1 May 2018
Amsterdam, NL – Ibuprofen, aspirin, and other non-steroidal anti-inflammatory medications are among the most commonly utilized medications in the United States. Primarily for treating pain, inflammation, and preventing cardiovascular disease, NSAIDs’ promising anti-cancer properties have been highlighted by a growing body of data in recent years. However, a new study in the journal Kidney Cancer indicated that non-aspirin NSAID use was associated with shorter overall survival in patients with metastatic renal cell carcinoma (mRCC).
Few studies have evaluated the effect of NSAIDs on patients with localized renal cell carcinoma (RCC); none have had characterized outcomes for patients with mRCC. To explore the effect of NSAIDs on outcomes of patients with mRCC, researchers investigated their use in 4,736 patients from a pooled database of patients treated on phase II-III clinical trials of targeted therapy agents.
According to the lead investigator Rana R. McKay, MD, Assistant Professor of Medicine, University of California San Diego, Moores Cancer Center, La Jolla, CA, USA, “The clinical trials database utilized in our analysis is a powerful tool to investigate clinically relevant questions. In the era of drug repurposing, evaluating the impact of agents that have the potential to demonstrate anti-cancer activity in patients is clinically meaningful. Our study, which is the largest to date investigating the impact of NSAIDs on mRCC, demonstrates that the use of non-ASA (non-aspirin) NSAIDs reduced overall or progression-free survival time for patients with metastatic disease, compared to patients who do not use NSAIDs.”
The association of the use of non-ASA NSAIDs with reduced survival was consistent when looking at untreated or previously treated patients, and also when looking at the type of targeted therapy received, either vascular endothelial growth factor (VEGF) or mammalian target of rapamycin (mTOR) targeted therapy. This may be explained by non-ASA NSAIDs’ kidney-specific toxicity profile and their potency, which can cause increased blood pressure and decreased renal function.
The study also concluded that aspirin did not provide a survival advantage or have an apparent anti-cancer effect for mRCC patients, even though previous epidemiological data demonstrates that aspirin use decreases incidence, metastasis, and mortality risk in several cancers. They point to NSAID nephrotoxicity as a possible cause and posit that the dose required for tumor-growth inhibition may be larger than the dose needed for the analgesic effect or cardiovascular disease prevention.
The anti-tumorigenic mechanism of NSAIDs has been largely attributed to their cyclooxygenase (COX) inhibitory activity, which leads to the suppression of prostaglandin synthesis, and ultimately decreases inflammation, although there are some differences in the inhibitory actions of ASA and non-ASA NSAIDs. In RCC, COX-2 expression is present in the majority of the tumors and correlates with poorer survival and other negative factors.
The investigators advise that “while thought-provoking, these results should be interpreted cautiously as hypothesis-generating rather than definitive and highlight the need for studies investigating the mechanisms of action underlying our observation.” They also recommend: “Prior to starting a new medication in any patient, a discussion needs to take place regarding the potential risks and benefits of that agent. This is especially true for non-aspirin NSAIDs in patients with RCC.”
NOTES FOR EDITORS
Full open access study:“Impact of Aspirin and Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs on Outcomes in Patients with Metastatic Renal Cell Carcinoma,” by Lana Hamieh, Raphael B. Moreira, Xun Lin, Ronit Simantov, Toni K. Choueiri, and Rana R. McKay, published in Kidney Cancer, Volume 2, Issue 1 (2018) (doi: 10.3233/KCA-180027) by IOS Press. The open access article is available at: https://content.iospress.com/articles/kidney-cancer/kca180027
This work was supported by Pfizer, Inc. Additionally, this research was supported in part by the Dana-Farber/Harvard Cancer Center Kidney SPORE, and the Trust Family, Michael Brigham, and Loker Pinard Funds for Kidney Cancer Research at Dana-Farber Cancer Institute for Toni K.Choueiri.
For additional information, contact Diana Murray, IOS Press (+1 718 640-5678 or firstname.lastname@example.org). Journalists wishing to interview the study’s authors should contact Lauren Stewart (+1 858-822-6185 or email@example.com).
About Kidney Cancer
Kidney Cancer is an international multidisciplinary journal to facilitate progress in understanding the epidemiology/etiology, genetics, molecular correlates, pathogenesis, pharmacology, ethics, patient advocacy and survivorship, diagnosis, and treatment of tumors of the kidney. The journal is dedicated to providing an open forum for original research in basic science, translational research, and clinical medicine that will expedite our fundamental understanding and improve treatment of tumors of the kidney. It journal publishes research reports, reviews, short communications, and Letters to the Editor. journalkidneycancer.com
About IOS Press
IOS Press is headquartered in Amsterdam with satellite offices in the USA, Germany, India, and China and serves the information needs of scientific and medical communities worldwide. IOS Press now publishes over 100 international journals and about 75 book titles each year on subjects ranging from computer sciences and mathematics to medicine and the natural sciences. iospress.com